EOM Pharmaceuticals Holdings, Inc.
IMUCOTCHealthcare● Active
$0.25
+$0.05(+25.00%)
Market Cap$28317750
P/E Ratio—
52W High$0.34
52W Low$0.036
EOM Pharmaceuticals Holdings, Inc. (IMUC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMUC · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2018Report Date: Aug 13, 2018EPS Actual
-$0.10
Revenue
—
Fiscal Period
Q3 FY2018
FY ends December
Report Date
Aug 13, 2018
After Market Close
IMUC reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q3 FY2018 | Aug 13, 2018 | — | -$0.10 | — | — | — | — |
| — Q2 FY2018 | May 14, 2018 | — | -$0.20 | — | — | — | — |
| — Q1 FY2018 | Mar 13, 2018 | — | -$0.10 | — | — | — | — |
| — Q4 FY2017 | Nov 21, 2017 | — | -$4.00 | — | — | — | — |
| — Q3 FY2017 | Aug 14, 2017 | — | -$10.20 | — | — | — | — |
| — Q2 FY2017 | May 15, 2017 | — | -$16.40 | — | — | — | — |
| ▼ Q1 FY2017 | Mar 9, 2017 | -$12.00 | -$13.60 | -13.3% | — | — | — |
| ▲ Q4 FY2016 | Nov 10, 2016 | -$20.00 | -$16.00 | +20.0% | — | — | — |
Q3 FY2018
Aug 13, 2018
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2018
May 14, 2018
EPS Actual
-$0.20
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2018
Mar 13, 2018
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2017
Nov 21, 2017
EPS Actual
-$4.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2017
Aug 14, 2017
EPS Actual
-$10.20
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2017
May 15, 2017
EPS Actual
-$16.40
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2017
Mar 9, 2017Miss
EPS Actual
-$13.60
EPS Est.
-$12.00
EPS Surpr.
-13.3%
Revenue
—
Q4 FY2016
Nov 10, 2016Beat
EPS Actual
-$16.00
EPS Est.
-$20.00
EPS Surpr.
+20.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2018 | Aug 13, 2018 | — | No price data | — | — |
| — Q2 FY2018 | May 14, 2018 | — | No price data | — | — |
| — Q1 FY2018 | Mar 13, 2018 | — | No price data | — | — |
| — Q4 FY2017 | Nov 21, 2017 | — | No price data | — | — |
| — Q3 FY2017 | Aug 14, 2017 | — | No price data | — | — |
| — Q2 FY2017 | May 15, 2017 | — | No price data | — | — |
| ▼ Q1 FY2017 | Mar 9, 2017 | -13.3% | No price data | — | — |
| ▲ Q4 FY2016 | Nov 10, 2016 | +20.0% | No price data | — | — |
Q3 FY2018—
Report Date
Aug 13, 2018
EPS Beat/Miss
—
Price Before
—
Price After
—
Q2 FY2018—
Report Date
May 14, 2018
EPS Beat/Miss
—
Price Before
—
Price After
—
Q1 FY2018—
Report Date
Mar 13, 2018
EPS Beat/Miss
—
Price Before
—
Price After
—
Q4 FY2017—
Report Date
Nov 21, 2017
EPS Beat/Miss
—
Price Before
—
Price After
—
Q3 FY2017—
Report Date
Aug 14, 2017
EPS Beat/Miss
—
Price Before
—
Price After
—
Q2 FY2017—
Report Date
May 15, 2017
EPS Beat/Miss
—
Price Before
—
Price After
—
Q1 FY2017—
Report Date
Mar 9, 2017
EPS Beat/Miss
-13.3%
Price Before
—
Price After
—
Q4 FY2016—
Report Date
Nov 10, 2016
EPS Beat/Miss
+20.0%
Price Before
—
Price After
—
Beat Rate1 / 8 quarters
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMUC ends December
EOM Pharmaceuticals Holdings, Inc. (IMUC) most recently reported earnings on August 13, 2018 for Q3 FY2018, posting EPS of $-0.10 (in line with the analyst consensus of —). The next IMUC earnings date is expected around September 1, 2026.
Each quarter, investors track IMUC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMUC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMUC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMUC earnings · 3 questionsEOM Pharmaceuticals Holdings, Inc.'s next earnings report is expected around September 1, 2026. IMUC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMUC historically reports after market close (AMC).
IMUC earnings datewhen is IMUC earningsIMUC next earnings datewhen does IMUC report earningsIMUC earnings calendar
▸ Source: FMP · EOM Pharmaceuticals Holdings, Inc. SEC filings · US GAAP · EOM Pharmaceuticals Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026